CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH UNDIAGNOSED DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES
The Indonesian Journal of General Medicine · 20.11.2026 · 44 (2) · 612-674
DOI: 10.70070/xpb8rr96 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, online erschienen am 20.11.2026. Verfasst von Indra Pehulisa Sitepu und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Up to one in six patients hospitalised with acute coronary syndrome (ACS) has diabetes mellitus (DM) that was never diagnosed before the index event. Whether undiagnosed DM (UDM) carries the same prognostic burden as normoglycaemia or as previously known DM remains controversial, because published cohorts differ in diagnostic criteria, timing of glycaemic testing, and comparators. We aimed to quantify the prevalence of UDM in ACS and its association with short- and long-term clinical outcomes compared with patients without DM and with known DM.
Methods
This systematic review and meta-analysis followed the PRISMA 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched (January 2011–October 2026) and supplemented by citation searching. RCTs (including secondary analyses), comparative studies, cohorts and case series reporting outcomes separately for UDM were eligible. Risk of bias was appraised with the Newcastle–Ottawa Scale (NOS). Crude risk ratios (RR) and adjusted hazard/odds ratios were pooled separately with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) intervals, prediction intervals, subgroup, leave-one-out, cumulative and meta-regression analyses, and assessment of small-study effects. Certainty of evidence was graded with GRADE.
Results
Eighteen studies (two post hoc analyses of RCTs and 16 cohorts/registries; 169,908 participants, ≥14,345 with UDM) were included. The pooled prevalence of UDM among ACS patients without known DM was 9.1% (95% CI 6.3–13.1%), reaching 19.3% when an oral glucose tolerance test (OGTT) was used. Compared with patients without DM, UDM was associated with higher adjusted long-term all-cause mortality (HR 1.48 (1.24–1.77); k = 6; I² = 34%), higher crude long-term mortality (RR 1.59 (1.17–2.16)), more major adverse cardiovascular events (MACE; adjusted ratio 1.27 (1.07–1.51); k = 10; I² = 75%) and more heart failure (RR 1.51 (1.20–1.89); I² = 0%). No significant differences were found for 30-day mortality (RR 1.18 (0.53–2.59)), in-hospital mortality (1.08 (0.66–1.76)), reinfarction (1.43 (0.83–2.47)), stroke (1.37 (0.70–2.68)) or cardiovascular death (1.32 (0.82–2.11)). Compared with known DM, UDM conferred lower long-term mortality (RR 0.77 (0.61–0.96)) and fewer reinfarction/recurrent ACS events (RR 0.58 (0.42–0.79)), with similar short-term mortality and MACE. Against a common non-diabetic reference, adjusted ratios were 1.14 (0.90–1.43) for UDM and 1.45 (1.18–1.77) for known DM. Trim-and-fill attenuated the MACE estimate to 1.16 (0.96–1.39).
Discussion
UDM identifies an intermediate-risk ACS phenotype whose excess hazard emerges predominantly after discharge and is expressed as all-cause death and heart failure rather than early mortality. The magnitude of risk depends on the diagnostic strategy, the comparator, and the degree of statistical adjustment, which explains much of the discordance among previous reports. Fewer than half of UDM patients received glucose-lowering therapy at discharge in the cohorts that reported it.
Conclusion
Undiagnosed DM is common in ACS and is associated with approximately 50% higher long-term mortality and higher rates of MACE and heart failure than normoglycaemia, although risk remains lower than that of established DM. Systematic in-hospital screening with HbA1c and fasting glucose, complemented by OGTT when HbA1c is non-diagnostic, followed by guideline-directed cardiometabolic therapy, is warranted. Certainty of evidence is low for mortality and heart failure and very low for other outcomes.
Zitieren
APA
Sitepu, I. P., Wicaksono, E. O., & Malik, A. (2026). CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH UNDIAGNOSED DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The Indonesian Journal of General Medicine, 44(2), 612-674. https://doi.org/10.70070/xpb8rr96
Vancouver
Sitepu IP, Wicaksono EO, Malik A. CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH UNDIAGNOSED DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES. The Indonesian Journal of General Medicine. 2026;44(2):612-674. doi:10.70070/xpb8rr96
BibTeX
@article{Sitepu2026,
author = {Sitepu, Indra Pehulisa and Wicaksono, Eko Oktiawan and Malik, Azizah},
title = {CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH UNDIAGNOSED DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES},
journal = {The Indonesian Journal of General Medicine},
year = {2026},
volume = {44},
number = {2},
pages = {612--674},
doi = {10.70070/xpb8rr96}
}
EUVIMED